Summary
Most patients with advanced ovarian cancer suffered recurrences. Therefore, adjuvant therapy is recommended for all patients with advanced ovarian cancer. Traditionally, intravenous paclitaxel + carboplatin has been the standard adjuvant therapy. Recently, intraperitoneal combination chemotherapy has been reported to be effective in ovarian cancer. We attempted to evaluate the efficacy and feasibility of standard intravenous paclitaxel + carboplatin plus intraperitoneal paclitaxel chemotherapy.
Key Facts
Lead Sponsor
Enrollment
Start Date
Completion Date
Study Type
Official Title
Interventions
Conditions
Eligibility
Age Range
Sex
Inclusion criteria: 1. Age \>=20 and \<=75 2. Histologically confirmed epithelial ovarian cancer, primary peritoneal carcinoma, tubal cancer 3. Stage 3 or 4 4. WBC \>= 3500/mm3, ANC \>= 1500/mm3, platelet \>= 100000/mm3, hemoglobin \>= 10 g/dl 5. Serum creatinine \<= upper normal limit \* 1.25 6. Total bilirubin \<= 1.5mg/mm3, ALT/AST \<= upper normal limit \* 3, ALP \<= upper normal limit \* 3 7. Adequate compliance and geographical closeness which make adequate follow-up possible 8. GOG performance status 0-2 9. Anticipated survival \>= 3 months 10. Who agreed to participate in this study and signed on informed consent form Exclusion criteria: 1. History of chemotherapy or radiotherapy on abdomen/pelvis area 2. Pleural/pericardial effusion, ascites causing respiratory difficulties \>= NCI-CTCAE grade 2 3. History of other cancers within 5 years 4. History of unapproved therapy within 30 days before enrollment 5. Other serious diseases which could threat the safety of participants or impair the ability of participants to complete the participation.